scout
|Videos|April 15, 2021

Case-Based Peer Perspectives: 57-Year-Old Man With ALK+ Non–Small Cell Lung Cancer

Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME